【摘要】 目的探讨不同联合用药方案治疗顽固性高血压的临床疗效及安全性。方法筛选我院收治的顽固性高血压患者150例作为研究对象。随机分为A、B、C组,每组50例,其中A组单纯应用硝苯地平控释片(拜新同)治疗,B组采用拜新同联合厄贝沙坦氢氯噻嗪片(依仑平),C组应用拜新同联合琥珀酸美托洛尔缓释片(倍他乐克),比较三组治疗效果及药物不良反应发生情况。结果 B、C组治疗总有效率、血压控制效果均优于A组(P<0.05),并且B组治疗总有效率、血压控制效果优于C组(P<0.05);三组均未发生严重不良反应,不良反应发生率比较差异无统计学意义(P>0.05)。结论拜新同联合依仑平可获得良好的血压控制效果以及药物治疗效果,并且安全性较高。更多还原

【Abstract】 Objective To explore the clinical efficacy and safety of different combination schemes in treatment of refractory hypertension. Methods 150 cases of patients with refractory hypertension in our hospital were taken as the research object and randomly divided into A, B, C group, 50 cases in each group, the A group was treated with Nifedipine Controlled Release Tablets(Adalat), group B was treated with Adalat combined with Irbesartan and Hydrochlorothiazide Tablets, C group was treated with Adalat combined with Metoprolol Succinate Sustained-release Tablets(Betaloc), the occurrence of adverse reactions and drug treatment effects were compared between the three groups. Results The total effective rate, the blood pressure control in B, C group were significantly better than that of A Group(P<0.05), and the total effective rate of B group, the blood pressure control effect were better than that of C group(P<0.05). There were no serious adverse reactions in the three groups, and there was no significant difference in the incidence of adverse reactions(P>0.05). Conclusion The effect of good blood pressure control and drug treatment can be obtained by the combination of Adalat and Yi Lunping, and have high safety.更多还原